A Study to Evaluate the Impact of Lactobacillus Rhamnosus GG on Proton Pump Inhibitor-Induced Gut Dysbiosis

Recruiting now · Not applicable · Has a placebo group

Conditions studied: Healthy

In brief

The purpose of this study is to investigate the impact of the probiotic Lactobacillus rhamnosus (LGG) on proton pump inhibitor (PPI)-induced changes to the microbes that live in the gastrointestinal tract and are passed out in the stool. PPI medicines reduce stomach acid and are commonly used to treat acid reflux disease.

Key facts

Study ID

NCT05517928

Run by

Mayo Clinic

People needed

30

Starts

2023-03-03

Expected to finish

2026-12-01

Last updated by the study team

2026-01-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Individuals on an unrestricted regular diet with no dietary restrictions (vegan, low FODMAP, gluten free, dairy-free etc) or other fad diets (e.g., keto, intermittent fasting, etc.).
• Healthy subjects will be screened for current or chronic GI symptoms using a 16-item questionnaire.
• Only those with an absence of symptoms will eligible to participate.

You may not qualify if…

• For healthy volunteers, will include prior surgery altering the esophagus, stomach, and intestine (except appendectomy).
• Chronic daily use of medications affecting GI secretion or motor function.
• The presence of any GI-motility affecting systemic diseases or untreated psychiatric disease.
• Pregnancy.

Where it is running

• Mayo Clinic Arizona — Scottsdale, Arizona, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.